Cybin D/B/A Helus Pharma
HELPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cybin D/B/A Helus Pharma focuses on Biotechnology services and products. Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. Valued at $242.0M, HELP is a micro-cap name in its sector. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
Market Cap
$242.0M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-1.56
EPS (TTM)
$-4.30
EPS (Fwd)
$-3.10
ROE
-55.9%
ROA
-31.9%
Cash
$206,357
Total Debt
$0
Free CF
-$70.0M
52W Change
-38.1%
Annual Financials
Cash vs Debt
Cybin D/B/A Helus Pharma reports $206K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$70.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cybin D/B/A Helus Pharma's trajectory.